Table 1.
Characteristics of the Study Population
| Characteristic | EI-AED | NEI-AED | p-value |
|---|---|---|---|
| Number, n | 10 | 25 | |
| Demographics (n, % or mean ± SD) | |||
| Age at HIV diagnosis (y) | 31.8 ± 11.4 | 32.8 ± 7.7 | 0.765 |
| Age at first AED/ARV overlap (y) | 41.9 ± 11.3 | 46.8 ± 9.2 | 0.190 |
| Female | 1 (10.0) | 3 (12) | 0.869 |
| Race/ethnicity | 0.247 | ||
| European American | 7 (70) | 10 (40) | |
| African American | 3 (30) | 13 (52) | |
| Other | 0 (0) | 2 (8) | |
| Year of HIV diagnosis (median, range) | 1988 (1985 - 2000) | 1991 (1986 - 2005) | 0.541 |
| CD4 count at HIV diagnosis (cells/uL) | 376 ± 141 | 534 ± 353 | 0.344 |
| CD4 count at first AED/ARV overlap (cells/uL) | 377 ± 258 | 397 ± 226 | 0.834 |
| Viral load (log10) at first AED/ARV overlap (copies/mL) | 3.6 ± 1.4 | 3.1 ± 1.7 | 0.450 |
| AIDS-defining event prior to first AED/ARV overlap | 5 (50) | 11 (44) | 0.751 |
| Number of AED/ARV overlap periods per participant (n, %) | 0.212 | ||
| 1 | 5 (50.0) | 20 (80) | |
| 2 | 4 (40.0) | 5 (20) | |
| 3 | 1 (10.0) | 0 (0) | |
| Months of AED/ARV overlap, all participant overlaps (median, range) | 19.6 (3.8 - 155.4) | 26.8 (3.1 - 83.3) | 0.688 |
| Days from start of first AED/ARV overlap to measurement of serum drug levels (median, IQR) | 112.5 (73-261) | 126.0 (55-178) | 0.784 |
| ARV regimens (n, %) | 0.831 | ||
| PI-based | 4 (40.0) | 11 (44) | |
| NNRTI-based | 6 (60.0) | 14 (56) |
EI-AED, enzyme-inducing antiepileptic drug; NEI-AED, non enzyme-inducing antiepileptic drug (gabapentin); ARV, antiretroviral drug; NNRTI, non-nucleotide reverse transcriptase inhibitors; PIs, protease inhibitors